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Background: In a recent trial of artemisinin-naphthoquine (artemisinin-NQ) and artemether-lumefantrine (AM-LM)
therapy in young children from Papua New Guinea (PNG), there were no treatment failures in artemisinin-NQ-treated
children with Plasmodium falciparum or Plasmodium vivax compared with 2.2% and 30.0%, respectively, in
AM-LM-treated children during 42 days of follow-up. To determine whether, consistent with the long elimination
half-life of NQ, this difference in efficacy would be more durable, clinical episodes of malaria were assessed in a subset
of trial patients followed for six months post-treatment.
Methods: For children completing trial procedures and who were assessable at six months, all within-trial and
subsequent clinical malaria episodes were ascertained, the latter by clinic attendances and/or review of
hand-held health records. Presentations with non-malarial illness were also recorded. Differences between
allocated treatments for pre-specified endpoints were determined using Kaplan-Meier survival analysis.
Results: Of 247 children who were followed to Day 42, 176 (71.3%) were included in the present sub-study, 87
allocated to AM-LM and 89 to artemisinin-NQ. Twenty children in the AM-LM group (32.8%) had a first episode
of clinical malaria within six months compared with 10 (16.4%) in the artemisinin-NQ group (P = 0.033, log rank
test). The median (interquartile range) time to first episode of clinical malaria was 64 (50–146) vs 116 (77–130)
days, respectively (P = 0.20). There were no between-group differences in the incidence of first presentation with
non-malarial illness (P = 0.31).
Conclusions: The greater effectiveness of artemisinin-NQ over conventional AM-LM extends to at least six
months post-treatment for clinical malaria but not non-malarial illness.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12610000913077.
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Artemisinin-based combination therapy (ACT) has
emerged as first-line treatment for uncomplicated mal-
aria in most malaria-endemic countries because of the
high cure rate, relative safety, transmission-blocking
potential, and ability to delay the development of parasite
drug resistance [1]. Its place in management of malaria
has been cemented through randomized clinical trials, but
there is uncertainty regarding the optimal duration of
follow-up for determining efficacy. The World Health
Organization (WHO) currently recommends Day 42 as
the maximum follow-up time-point for trials involving
longer half-life ACT partner drugs [2,3], but there is the-
oretical evidence that at least 56 days of follow-up should
be considered for trials of falciparum malaria involving
ACT partner drugs with elimination half-lives that are
longer than one week [4]. In the case of vivax malaria, and
in trials of falciparum malaria in areas where Plasmodium
vivax is transmitted, late post-treatment recurrences can
result from relapses from dormant liver stages. Durations
of follow-up of up to 63 days have been employed in this
situation [5]. However, a longer duration of follow-up
increases the complexity and cost of clinical trials, while
attrition rates of patients, and also trained research staff
[6], are likely to increase.
In a recent comparative efficacy and safety trial of
three daily doses of artemisinin-naphthoquine (artemisi-
nin-NQ) and conventional artemether-lumefantrine
(AM-LM) therapy in young children from north coastal
Papua New Guinea (PNG) with uncomplicated falcip-
arum and/or vivax malaria [7], there were no reappear-
ances of asexual forms of either Plasmodium falciparum
or P. vivax during the WHO-recommended 42 days of
follow-up in any child in the artemisinin-NQ group. The
greater number of recurrent infections after AM-LM
may have reflected the shorter elimination half-life of
LM compared with NQ (4–5 days [8] vs 21–25 days
[9]). To assess this possibility and in light of the possible
need for prolonged follow-up in such ACT trials [4], a
subset of trial participants were followed for a period of
six months post-treatment. It was hypothesized that, in
coastal PNG where malaria transmission is at least moder-
ate and recurrent malaria in children aged ≤5 years is
common [10], the incidence of clinical episodes of malaria
during prolonged follow-up would reflect the elimination
half-life of the non-artemisinin partner drug.
Methods
Study setting, design and approvals
The present study was conducted at Mugil and Alexishafen
Health Centres in Madang Province on the north coast of
mainland PNG. The malaria entomological inoculation
rate (EIR) in this setting has been estimated at 37 for P.
falciparum and 24 for P. vivax [10]. Although there hasbeen a significant decline in falciparum malaria after the
introduction of malaria control programs, the incidence of
vivax malaria has remained unchanged over the last three
decades [10,11].
The parent trial was a randomized, comparative, efficacy
trial of AM-LM and artemisinin-NQ (Australian New
Zealand Clinical Trials Registry ACTRN12610000913077)
[7]. In the present sub-study, all children completing trial
procedures were followed subsequently for two primary
outcomes; i) the cumulative incidence of clinical episodes
of malaria within-trial (up to Day 42) and post-trial (up to
6 months after treatment), and ii) the median time to the
clinical episodes of malaria within six months of allocated
treatment. Secondary outcomes were; i) the incidence of
non-malarial illness between treatment groups within six
months of allocated treatment, and ii) the median time to
episodes of a non-malarial illness within six months of
allocated treatment. Both the parent trial and present sub-
study were approved by the PNG Institute of Medical Re-
search Review Board, the PNG Medical Research Advisory
Committee (MRAC 10.39) and the University of Western
Australia Human Research Ethics Committee. Written in-
formed consent was obtained from parents/guardians of
all children before participation.
Patients
Children aged between 6 months and 5 years with un-
complicated malaria were recruited to the parent trial
between March 2011 and April 2013 provided that they
had; i) an axillary temperature >37.5°C or fever during
the previous 24 hours, ii) P. falciparum (>1,000 asexual
parasites/μL whole blood) and/or P. vivax (>250/μL) on
a peripheral blood smear, iii) not used study drugs in the
past 14 days, and iv) no clinical or laboratory evidence
of severe malaria or other infection [7].
Within-trial clinical and laboratory procedures
Within-trial clinical and laboratory procedures have
been described previously [7]. Briefly, children were ran-
domly assigned by use of a computer-generated random
numbers in blocks of 24 by site to receive AM-LM
(1.7:10 mg/kg; Novartis Pharma, Basel, Switzerland)
twice-daily for three days with milk as per manufac-
turer’s recommendation or artemisinin-NQ (20:8 mg/kg;
Kunming Pharmaceutical Corporation, Yunnan, China)
daily with water for three days. Treatment allocation was
concealed from investigators by use of an opaque, sealed,
and sequentially numbered envelope that was opened
only after the patient was enrolled. Serial clinical and la-
boratory assessments including axillary temperature and
malaria microscopy were performed on Days 1, 2, 3, 7,
14, 28 and 42.
Early treatment failure was defined as the development
of signs of severity or an inadequate parasitological
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sitaemia between Days 4 and 42 was considered to
have late parasitological failure or, if febrile (axillary
temperature >37.3°C), late clinical failure. Children
without any of the above WHO definitions of treat-
ment failure were considered to have an adequate clin-
ical and parasitological response (ACPR). Plasmodium
falciparum re-infection and recrudescence were distin-
guished using polymerase chain reaction genotyping of
merozoite surface proteins (MSP1 and MSP2) based on
paired samples collected on Day 0 and at reappearance
during the active follow-up period [13,14]. Plasmo-
dium vivax recrudescence was determined based on
genotyping of MSP1F3 and Microsatellite 16 [15].
Malaria blood smears were examined independently by
two skilled microscopists [7]. The WHO-recommended
method of parasite density calculation based on the num-
ber/200-500 leucocytes and an assumed leucocyte count
of 8,000/μL [16] was used and has been validated for the
study setting [17].
Post-trial follow-up
During the post-trial follow-up period, parents/guardians
were asked to bring their children back to the Mugil or
Alexishafen Health Centres if the child became unwell
or developed fever within the six months after allocated
treatment. In all these cases, field microscopy for malaria
parasites or a malaria rapid diagnostic test (RDT;
CareStart® HRP-2/pLDH (Pf/pan) Combo Test, AccessBio,
Somerset, NJ, USA) was performed. All malarial and non-
malarial illnesses during the post-trial follow-up period
were treated according to PNG national guidelines [18].
Initially, the parents/guardians of the children who did
not re-attend with an illness within six months were vis-
ited in their villages at the end of this period and their
child’s health record books were examined to document
malarial or non-malarial illnesses that may have been
missed due to attendance at another health care facility.
However, this practice was discontinued because of lo-
gistic difficulties and the fact that an additional primary
endpoint was identified in less than <1% of these cases.
However, those children still within the six-month
follow-up period when the Mugil and Alexishafen
Health Centres closed (on Day 42 of the last randomized
patient) were excluded from the present study because
all their post-trial outcomes could not be ascertained.
Statistical analysis
Data are presented as mean ± SD or median [inter-quartile
range]. Two-sample comparisons for normally-distributed
variables were by Student’s t-test, for non-normally
distributed variables by Mann Whitney U-test, and for pro-
portions by Fisher’s exact test. Differences between allo-
cated treatments for pre-specified primary and secondaryendpoints were determined using Kaplan-Meier survival
analysis and the log rank test. All P-values are two-tailed
and unadjusted for multiple comparisons.
Results
Patients
Of the 267 children randomized in the parent trial, 247
(92.5%) were followed to Day 42. Of this latter number,
176 (71.3%) were included in the six month analysis,
comprising 87 allocated to AM-LM and 89 to
artemisinin-NQ (see Figure 1). The 71 children who
were excluded were those who had not attended the
Mugil and Alexishafen Health Centres post-trial and
were still within the six month follow-up period when
the two clinics closed at the end of the parent trial.
There were no deaths or non-infection-related clinic
attendances amongst the 176 included children, and
no differences in baseline characteristics by allocated
treatment except that more artemisinin-NQ-treated
children presented with vivax malaria (see Table 1).
Episodes of clinical malaria
In the AM-LM group, 20 (32.8%) children had a first
episode of clinical malaria (due to either P. falciparum
or P. vivax) within six months of treatment (see Table 2).
This included 4 who developed clinical malaria within-
trial [7], 12 who developed clinical malaria post-trial,
and 4 who were recorded as late parasitological failure
during the trial without being treated and who subse-
quently developed clinical malaria during the post-trial
period on Days 56, 62, 140 and 154, respectively. Of
these 20 patients, 18 (90%) had falciparum malaria and
two (10%) had vivax malaria at enrolment. In the
artemisinin-NQ group, there was no late parasitological
or clinical failure during the 42 days within-trial. How-
ever, 10 children developed clinical malaria between
Days 52 and 152 (16.4%, P = 0.046 vs AM-LM; see
Table 2). Of these 10 patients, five (50%) had falciparum
malaria, four (40%) had vivax malaria and 1 (10%) had a
mixed species infection at baseline. Kaplan-Meier ana-
lysis showed that the incidence of a first episode of clin-
ical malaria during six months of follow-up was higher
in the AM-LM group (P = 0.033 by log rank test; see
Figure 2). The median time to the first episode of clinical
malaria was 64 days in the AM-LM and 116 days in the
artemisinin-NQ group (P = 0.20; see Table 2).
If only those children who had an ACPR at Day 42 in
the parent trial were considered, 12 of the 37 in the
AM-LM group (32.4%) and 10 of 89 in the
artemisinin-NQ group (11.2%) had an episode of clin-
ical malaria between six weeks and six months after
treatment (P = 0.008).
From the available data relating to species of Plasmo-
dium detected in the 30 patients who developed clinical
Figure 1 Profile of patients followed from randomization to the end of the six-month follow-up period.
Laman et al. Malaria Journal  (2015) 14:121 Page 4 of 7malaria during follow-up, these children were classified
as belonging to one of five sub-groups; i) definite P.
falciparum (slide or RDT positive for this species), ii)
definite P. vivax (slide or RDT positive for this species),
iii) definite mixed P. falciparum/P.vivax (slide positive
for these species), iv) P. falciparum with or without P.
vivax (an RDT reported as ‘mixed’ since the presence of
both HRP-2 and pan-pLDH lines indicates an infection
with P. falciparum, or a mixed infection including P. fal-
ciparum), and v) unknown (RDT recorded as positive
without further details in the health record book). There
was no difference between the proportions of children in
each category by allocated treatment (see Table 3; P = 0.12
by Fisher’s exact test). In 19 out of the 30 cases (63.3%),
there was definite slide or RDT evidence of P. falciparum
infection.Table 1 Baseline characteristics of children who completed si
Artemether-lumefantrine (n
Age (months) 41.4 ± 16.6
Male (%) 43 (49.4)
Falciparum malaria (%)* 80 (92.0)
Vivax malaria (%)* 10 (11.5)
Axillary temperature (°C) 38.3 ± 1.3
Weight (kg) 12.4 ± 2.5
Respiratory rate (/min) 31.1 ± 8.8
Pulse rate (/min) 122.8 ± 20.8
Mid upper arm circumference (cm) 14.5 ± 1.2
Height (cm) 93.1 ± 10.6
Body Mass Index (kg/m2) 14.4 ± 1.6
Palpable spleen ≥2 cm (%) 35 (40.2)
Haemoglobin (g/L) 89.8 ± 17.1
Blood glucose (mmol/L) 6.6 ± 1.8
Data are numbers (percentages) or mean ± SD.
*8 patients (3 artemether-lumefantrine-treated and 5 artemisinin-naphthoquine-treaEpisodes of non-malarial illness
Twenty-one (24.1%) and 16 (18.0%) of children in the
AM-LM and artemisinin-NQ groups, respectively, had a
first episode of non-malarial illness during the six-month
follow-up period (P = 0.36; see Table 1). Kaplan-Meier
analysis showed that the incidence of non-malarial
illness was not significantly different between groups
(P = 0.31 by log rank test). There was also no significant
between-group difference in the time to the first episode
of a non-malarial illness (medians 123 and 107 days, re-
spectively; see Table 2). Most had respiratory infections
(32.4%) or skin infections (24.3%). There were no dif-
ferences in the percentages of children who had more
than one non-malarial illness during follow-up (63.2%
in AM-LM group vs 55.1% in the artemisinin-NQ
group; P = 0.27).x months of follow-up classified by allocated treatment
= 87) Artemisinin-naphthoquine (n = 89) P-value




38.1 ± 1.4 0.51
12.6 ± 2.5 0.50
31.3 ± 10.1 0.97
122.5 ± 20.7 0.91
14.5 ± 1.2 0.97
93.0 ± 10.5 0.97
14.7 ± 2.1 0.38
38 (42.7) 0.76
94.0 ± 17.7 0.11
6.7 ± 1.8 0.71
ted) had mixed P. falciparum/P. vivax infections.
Table 2 Endpoints by allocated treatment for the 176 children with data for six months after trial entry
Artemether-lumefantrine (n = 87) Artemisinin-naphthoquine (n = 89) P-value
Primary outcome
Clinical malaria within six months following initial treatment 20/87 (23) 10/89 (11.2) 0.046
Median time to first malarial illness (days) 64 [50–146] 116 [77–130] 0.20
Secondary outcome
Incidence of non-malarial illnesses within six months 21/87 (24.1) 16/89 (18.0) 0.36
Median time to first non-malarial illness (days) 123 [80–149] 107 [92–166] 0.77
Data are number (percentage) or median [interquartile range].
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The present study shows that the relative clinical bene-
fits of artemisinin-NQ over conventional AM-LM
therapy extend well beyond the 42 days of the parent
trial. Artemisinin-NQ was associated with approxi-
mately half the risk of a first episode of clinical malaria
during follow-up over six months. The parallel nature
of the Kaplan-Meier curves and the between-treatment
difference in median time to first malarial episode sug-
gest that the long half-life of the NQ component of
artemisinin-NQ delays malaria post-treatment suscep-
tibility relative to AM-LM by 7–8 weeks. This is
equivalent to 2–3 NQ elimination half-lives in PNG
children [9]. In the patients allocated to AM-LM, the
relatively rapid elimination of LM and its active metab-
olite desbutyl-LM [8,19] is unlikely to afford protection
from reappearance of malaria or a new malarial infec-
tion beyond the 42 days of the parent trial. Despite the
higher haemoglobin concentrations in the artemisinin-
NQ group at the end of the parent trial [7] and theFigure 2 Kaplan-Meier survival analysis showing the proportions
of children treated with artemether-lumefantrine (solid line) and
artemisinin-naphthoquine (dashed line) remaining free of clinical
malaria during six months after allocated treatment. The P-value
for the log rank test is shown.recognized association between anaemia and bacterial
infection in young children in the tropics [20-22], there
was no protective effect of artemisinin-NQ treatment
on the risk of non-malarial (mainly bacterial) infec-
tions in patients in this study.
There is evidence that local malaria transmission in-
tensity may play a role in the efficacy of longer-acting
partner drugs [23,24]. In one trial in which patients were
followed up beyond Day 42 in an area of intense malaria
transmission in Uganda (P. falciparum EIR 562 [25]),
there was no difference in malaria reinfection rates
in children receiving AM-LM or dihydroartemisinin-
piperaquine at Day 63 despite the longer elimination
half-life of piperaquine [23]. In the more moderate
transmission setting of the present study (P. falciparum
EIR 37 [10]), the post-treatment prophylactic effect of NQ
was evident at Day 63 and beyond. However, the ability of
NQ to suppress relapses of P. vivax may have been a con-
tributor to the between-group differences in late clinical
malaria in the patients [7], a consideration not relevant to
sub-Saharan Africa. Unfortunately, the exact relative con-
tribution of P. vivax infections could not be ascertained
accurately because in 70% of cases the RDT was reported
as ‘mixed’ or simply positive.
Antimalarial drugs such as NQ with long elimination
half-lives are more likely to promote the development
of parasite resistance as a result of prolonged sub-
therapeutic plasma concentrations [26,27]. In the case
of PNG, chloroquine has provided a salutary example
in that sustained and widespread use has resulted inTable 3 Plasmodium species categorization of cases of
clinical malaria during follow-up, based on microscopy







Definite P. falciparum 2 (10%) 3 (30%)
Definite P. vivax 3 (15%) 0
Definite mixed species infection 0 1 (10%)
P. falciparum ± P. vivax 9 (45%) 4 (40%)
Unknown 6 (30%) 2 (20%)
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alternative treatments [28]. However, the ‘mandatory’
combination of newer long-acting drugs such as NQ with
an artemisinin derivative [1,3] is likely to be protective,
and even triple therapy regimens are being considered to
limit the possibility of parasite resistance [29]. The wide-
spread deployment of artemisinin-NQ in countries such
as PNG may be justifiable based on prolonged efficacy/
effectiveness such as demonstrated in the parent trial
[7] and present data, but in vivo, in vitro and/or genetic
monitoring of parasite resistance should be an integral
part of this process.
The present study had limitations. Neither accurate
differentiation between Plasmodium species nor geno-
typing to differentiate recrudescences from reinfections
was performed, but the primary endpoint (clinical
malaria) was a pragmatic one designed to allow the
long-term real-world effectiveness of the two treatment
regimens to be assessed. For logistic and financial rea-
sons, not all participants in the parent trial at each site
were followed for the full six months, but most children
were included and the two treatment groups were
similar in number and baseline characteristics. Indeed, the
significantly greater number of vivax cases in the
artemisinin-NQ group and the potentially high rate of asso-
ciated late relapses may have led to bias against this ACT,
but it nonetheless proved more effective than AM-LM.
Conclusion
The present study is one of the few published in the
literature that have employed long-term follow-up of pa-
tients with malaria treated with artemisinin combination
therapy. The data suggest strongly that the long terminal
elimination half-life of three daily doses of NQ confers
benefit of artemisinin-NQ over AM-LM to at least six
months post-treatment. This observation should favourably
influence cost-effectiveness analyses. In addition, the
present long-term follow-up data also add to the re-
assuring results of detailed safety monitoring over
42 days in the parent trial [7], in that there were no
unsuspected late sequelae after three daily doses of
artemisinin-NQ rather than the single dose recom-
mended by the manufacturer.
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